Cargando…
Nanotechnology-based targeted drug delivery systems for brain tumors.
Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors addresses brain anatomy and tumors and the progress and challenges in delivering drugs across the blood brain barrier. Several chapters are devoted to the latest technologies and advances in nanotechnology, along with practical sol...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
[Place of publication not identified] :
ELSEVIER ACADEMIC Press,
2018.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Intro; Title page; Table of Contents; Copyright; Dedication; List of Contributors; Biography; Preface; Chapter 1. Tumors of the Central Nervous System: Anatomy and Interventional Considerations; Abstract; 1.1 Introduction; 1.2 Cellular Composition of the CNS; 1.3 Gross Anatomy of the Human Brain; 1.4 Barriers to the CNS; 1.5 Brain Tumors; 1.6 Discussion; References; Chapter 2. Angiogenesis in Brain Tumors; Abstract; 2.1 Introduction; 2.2 Angiogenesis and the Central Nervous System; 2.3 Cellular and Molecular Mechanism of Angiogenesis in Brain Tumors.
- 2.4 Hypoxia, the Blood-Brain Barrier, and the Brain Tumor Vasculature2.5 Antiangiogenic Factors; 2.6 Angiogenic Balance and the Angiogenic Switch; 2.7 Angiogenesis in Primary Brain Tumors and Glioblastoma; 2.8 Angiogenesis in Glioblastoma; 2.9 Conclusion; References; Chapter 3. Physiology of the Blood-Brain Barrier and Mechanisms of Transport Across the BBB; Abstract; 3.1 The Blood-Brain Barrier; 3.2 Development of the BBB; 3.3 Physiology of the BBB; 3.4 Conclusions; References; Chapter 4. Active Targeted Nanoscale Delivery Systems for Brain Tumor Therapeutics; Abstract; 4.1 Introduction.
- 4.2 Receptor-Mediated Transcytosis Across the Blood-Brain Barrier4.3 Transferrin-Based Targeting; 4.4 Lactoferrin-Based Targeting; 4.5 Folic Acid-Based Targeting; 4.6 Antibody-Based Targeting; 4.7 Aptamer-Based Targeting; 4.8 Peptide-Based Targeting; 4.9 Clinical Perspective; References; Chapter 5. Nanotechnology in Brain Tumor Targeting: Efficacy and Safety of Nanoenabled Carriers Undergoing Clinical Testing; Abstract; 5.1 Nanoenabled Drugs in the Treatment of Brain Tumors; 5.2 Nanoparticle Delivery and Glioma Targeting; 5.3 Lipid-Based Nanomedicines; 5.4 Polymeric Nanomedicines.
- 5.5 Dendrimers5.6 Amino Acid- and Nucleic Acid-Based Nanomedicines; 5.7 Drug Conjugates; 5.8 Towards a Cure for Brain Tumors: Nanotechnology in the Operating Room and in the Clinic; References; Chapter 6. Targeting of Lipid/Polymeric (Hybrid) Nanoparticles to the Brain for the Treatment of Degenerative Diseases; Abstract; Acknowledgments; 6.1 Introduction; 6.2 Brain Targeting: Overcoming the Blood-Brain Barrier; 6.3 Nanoengineered Colloid Drug Delivery Systems; 6.4 Advances in Nanomedicines for Neurodegenerative Diseases; 6.5 Conclusions and Future Prospects; References.
- Chapter 7. Biopolymeric Nanoparticles for Targeted Drug Delivery to Brain TumorsAbstract; Acknowledgment; 7.1 Introduction; 7.2 Protein Nanocarriers for Drug Delivery to Brain Tumors; 7.3 Polysaccharide Nanocarriers for Drug Delivery to Brain Tumors; 7.4 Conclusions; References; Chapter 8. Solid Lipid Nanoparticles for Targeted Brain Drug Delivery; Abstract; 8.1 Introduction to the Blood-Brain Barrier; 8.2 Novel Drug Delivery System Approach: Nanoparticles; 8.3 Conclusion; References; Chapter 9. Liposome-Based Drug Delivery for Brain Tumor Theranostics; Abstract; 9.1 Introduction.